Clinical trials: Anticoagulant Drugs
Head Injury, Traumatic Brain Injury
Selective CT for Anticoagulated Head Injured Patients
The goal is to derive and a clinical decision rule for safe exclusion of traumatic brain injury without neuroimaging in head-injured ED patients who take anticoagulant medications. The objectives are to: 1.
- Conditions
- Head Injury, Traumatic Brain Injury, Intracranial Hemorrhage, Traumatic, Blunt Head Injury
- Trial name
- Can-SCAHn (NCT05364749)
- Where
- 7 sites in Canada
- Volunteers
- 4,000 people
- Sponsor
- Dr. Kerstin de Wit
Older Adults (65 Years and Older), Falls
Healthcare Services for Older People Who Have Fallen With Potential Head Injury
Every year, one in three older people (>65 years old) experience a fall. Older people may have long-term health conditions and take medications that can increase their risk of bleeding (blood thinners).
- Conditions
- Older Adults (65 Years and Older), Falls, Head Injury
- Trial name
- Anti-HI-Falls (NCT07111871)
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Portsmouth Hospitals NHS Trust
Venous Thromboembolic Disease
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients.
- Trial name
- BAT-VTE (NCT05627375)
- Testing
- Full-dose anticoagulant therapy (AC), Antiplatelet therapy (AP)
- Where
- 28 sites in France
- Volunteers
- 1,400 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Stable Target INR
Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling
Clinically relevant biomarkers for warfarin identified in this study will provide crucial leads for subsequent studies to assess their predictive value during anticoagulant therapy.
- Trial name
- NCT01964794
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas
Atrial Fibrillation (AF)
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to…
- Trial name
- PACIFIC-AF (NCT04218266)
- Testing
- BAY2433334, Apixaban
- Where
- 93 sites in Austria, Belgium and 12 more
- Volunteers
- 755 people
- Sponsor
- Bayer
SARS-COV-2
Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant
SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke…
- Trial name
- LA-COVID (NCT05075928)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Non-valvular Atrial Fibrillation
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial fibrillation patients with severe renal impairment, compared with DU-176b administered to non-valvular atrial fibrillation (NVAF) patients…
- Trial name
- NCT01857622
- Testing
- DU-176b 15mg, DU-176b 30mg, DU-176b 60mg
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Ischemia, Stroke
Edoxaban for TIA and Acute Minor Stroke
Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral…
- Conditions
- Ischemia, Stroke, Cerebral Infarction
- Trial name
- NCT02221102
- Testing
- Aspirin, edoxaban
- Where
- China
- Volunteers
- 3,700 people
- Sponsor
- Xijing Hospital
Anticoagulants and Bleeding Disorders
Bleeding Oral Anticoagulant Analyzer (BOA)
The quality of the reversion of these serious hemorrhagic accidents under oral anticoagulants depends on the adequate use of reversion products but also on the speed of obtaining hemostasis data allowing to evaluate the…
- Trial name
- BOA (NCT05026281)
- Testing
- Quantra analyzer
- Where
- 6 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Clermont-Ferrand
Thrombosis, Cancer
Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)
The purpose of this study is to help find how safe current practices are when managing blood thinners in people with cancer who are having surgery or medical procedures.
- Conditions
- Thrombosis, Cancer, Thrombosis, Deep Vein, Atrial Fibrillation (AF)
- Trial name
- ACE-HIGH (NCT07372716)
- Testing
- standardized perioperative anticoagulation management Guideline
- Where
- Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Effect of Different Reagents., Oral Anticoagulant Therapy
Differences in Coagulation Test Kits
The aim of this study is to assess the effect of Innovin® reagent on laboratory results when compared with the Thromborel® S.
- Trial name
- NCT01109667
- Where
- Turkey (Türkiye)
- Volunteers
- 350 people
- Sponsor
- Yuksek Ihtisas Hospital
Coronary Artery Disease, Atrial Fibrillation
Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation
The investigators hypothesize that reducing the duration of clopidogrel therapy from 6 months to 6 weeks after DES implantation is associated with improved clinical outcomes in patients on ASA and an oral anticoagulant.
- Trial name
- ISAR-TRIPLE (NCT00776633)
- Testing
- aspirin, clopidogrel, oral anticoagulation
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 614 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Kidney Disease
Safety Evaluation of Use Sodic Enoxaparin
The purpose of this study was to evaluate safety, not inferiority clinical and pharmacodynamic profile of the drug Enoxaparin Sodium produced by laboratory Blausiegel when compared with Clexane product, produced by Laboratory…
- Trial name
- Enoxaparin (NCT00673426)
- Testing
- Enoxaparin sodic
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Azidus Brasil
Lung Neoplasms, Esophageal Neoplasms
The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
The purpose of this study is to determine whether the use of different dose of LMWH compared with fondaparinux for thromboprophylaxis is efficacious and safety after thoracic surgery.
- Conditions
- Lung Neoplasms, Esophageal Neoplasms, Venous Thromboembolism
- Trial name
- NCT01267305
- Testing
- Fondaparinux, Nadroparin Calcium
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Shanghai Zhongshan Hospital
Hemorrhage
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
- Trial name
- NCT02104947
- Testing
- idarucizumab
- Where
- 176 sites in United States, Argentina and 31 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Lower Extremity Injuries, Venous Thromboembolism (VTE)
TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower Limb Trauma Requiring Immobilization
This is a prospective, multicenter, observational cohort study designed to externally validate the Trauma-Related Immobilization-related Prophylaxis (TRiP(cast)) score in Tunisian adults with acute lower-limb trauma requiring…
- Conditions
- Lower Extremity Injuries, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- TRiP-VALID (NCT07863115)
- Testing
- Low-Molecular-Weight Heparin (LMWH), Direct Oral Anticoagulants (DOACs), No Thromboprophylaxis Cohort
- Where
- Tunisia
- Volunteers
- 1,500 people
- Sponsor
- University of Monastir
Periprocedural Complication
Periprocedural Direct Oral Anticoagulant Management
Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between others.
- Trial name
- RA-ACOD (NCT03182218)
- Testing
- Direct oral anticoagulant
- Where
- 30 sites in Spain
- Volunteers
- 1,100 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Coagulation Abnormalities
Routine Preoperative Hemostatic Laboratory Evaluation Prior to Tonsillectomy or Adenoidectomy in Children
Routine analysis of coagulation profile is recommended before adenoidectomy, tonsillectomy or ventilation tubes insertion in children.
- Trial name
- NCT00972361
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- HaEmek Medical Center, Israel
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Atrial Fibrillation, Anticoagulant-induced Bleeding
Perioperative Management of Factor Xa Inhibitors
This study aims to analyze the safety and effectiveness of the discontinuation/resumption protocol of factor Xa inhibitors before and after invasive procedures/surgeries in non-valvular atrial fibrillation patients who are at…
- Trial name
- PERIXa (NCT05801068)
- Testing
- Factor Xa Inhibitor
- Where
- South Korea
- Volunteers
- 2,500 people
- Sponsor
- Seoul National University Hospital